Online citations, reference lists, and bibliographies.

Selection Of Excipients Based On The Biopharmaceutics Classification System Of Drugs

G. Baki, Sachin Chaudhari, Ripal Gaudana, Sai H.S. Boddu
Published 2015 · Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
Active agents have been considered the main ingredients of any therapeutic product since the early ages of formulation technology. However, the importance of the inactive ingredients has been realized during the last three decades. With the development and manufacturing of more intelligent and multifunction excipients, new ways became available for formulation technologists to increase the beneficial effects of drugs on human body. Many modern active agents have internal characteristics that significantly decrease their potential and theoretical bioavailability; however, today we have the widest variety of inactive ingredients that we can utilize in order to change these properties. The careful and educated selection of excipients might significantly influence the effect of the drugs, including hastening or delaying their onset of action, increasing their bioavailability by changing their physicochemical characteristics, and increasing their stability. In this chapter, we focus primarily on the factors determining and influencing bioavailability as well as the selection of excipients for formulating new dosage forms with enhanced therapeutic efficacy, based on the physicochemical properties of drugs. We will provide some examples from the scientific literature to demonstrate the achievements in this multidisciplinary area.
This paper references
10.1021/mp8001864
The use of drug metabolism for prediction of intestinal permeability (dagger).
Mei-Ling Chen (2009)
10.1136/gut.27.8.886
Transit of pharmaceutical dosage forms through the small intestine.
S. Davis (1986)
10.1016/j.jpba.2011.01.024
Physico-chemical characterization and in vitro/in vivo evaluation of loratadine:dimethyl-β-cyclodextrin inclusion complexes.
Á. Szabados-Nacsa (2011)
10.1016/S0168-3659(96)01599-4
Modified bile acids as carriers for peptides and drugs
W. Kramer (1997)
10.1042/BA20000014
Stabilizing effect of chemical additives against oxidation of lactate dehydrogenase
M. M. Andersson (2000)
10.1007/s11095-006-9041-2
Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model
X. Cao (2006)
10.1016/j.jconrel.2011.07.003
Recent advances and novel strategies in pre-clinical formulation development: an overview.
A. K. Shah (2011)
10.7326/0003-4819-109-6-471
Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS).
G. Lake-Bakaar (1988)
10.1016/S0939-6411(00)00076-X
Improving drug solubility for oral delivery using solid dispersions.
C. Leuner (2000)
10.1208/s12248-009-9144-x
Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World’s Top Oral Drugs
A. Dahan (2009)
10.1007/BF03190052
Guidances related to bioavailability and bioequivalence: European industry perspective
G. Ahr (2010)
10.1021/MP070028I
Biopharmaceutics classification of selected beta-blockers: solubility and permeability class membership.
Y. Yang (2007)
10.5414/CPP44071
Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers.
N. Petri (2006)
10.1023/A:1016256619309
The Effect of Different Concentrations of Mannitol in Solution on Small Intestinal Transit: Implications for Drug Absorption
D. Adkin (1995)
10.1016/S0928-0987(99)00076-7
The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver?
H. Blume (1999)
10.1021/MP0600182
A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan.
T. Takagi (2006)
10.3109/03639045.2011.569933
Formulation of tablets containing an ‘in-process’ amorphized active pharmaceutical ingredient
Orsolya Jójárt-Laczkovich (2011)
10.1016/0169-409X(92)90015-I
(C) Means to enhance penetration: (2) Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity
E. S. Swenson (1992)
10.1023/A:1016016404404
Pectin/Ethylcellulose Film Coating Formulations for Colonic Drug Delivery
Z. Wakerly (2004)
10.1016/j.ijpharm.2008.05.012
Gut instincts: explorations in intestinal physiology and drug delivery.
E. McConnell (2008)
10.1016/S1056-8719(00)00107-6
Drug-like properties and the causes of poor solubility and poor permeability.
C. Lipinski (2000)
10.1016/S0928-0987(01)00214-7
Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent.
Jichao Kang (2002)
10.1002/bit.260480511
Chemical instability of protein pharmaceuticals: Mechanisms of oxidation and strategies for stabilization.
S. Li (1995)
10.1002/tera.1420440209
Involvement of the intestinal microflora in nitrazepam-induced teratogenicity in rats and its relationship to nitroreduction.
S. Takeno (1991)
10.1007/s11095-004-9004-4
Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System
C. Wu (2004)
10.1007/BF01061761
The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon
R. Oberle (2005)
10.1177/0091270007299930
Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs.
B. Urquhart (2007)
10.1002/BDD.1803
Mechanistic analysis of solute transport in an in vitro physiological two‐phase dissolution apparatus
P. Langguth (2012)
10.1211/0022357055263
The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.
H. Lennernäs (2005)
10.1208/s12248-008-9020-0
Use of the Biopharmaceutical Classification System in Early Drug Development
M. S. Ku (2008)
10.1021/mp800122b
Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay.
Victoria E Thiel-Demby (2009)
10.1208/ps010203
Prediction of dissolution-absorption relationships from a continuous dissolution/Caco-2 system
M. Ginski (2008)
Mechanisms of absorption enhancement by medium chain fatty acids in intestinal epithelial Caco-2 cell monolayers.
T. Lindmark (1995)
10.3109/03639045.2012.683440
Self-nanoemulsifying drug delivery system of cefpodoxime proxetil containing tocopherol polyethylene glycol succinate
Amrita Narayan Bajaj (2013)
10.1016/j.jconrel.2009.10.005
Impact of emulsion-based drug delivery systems on intestinal permeability and drug release kinetics.
Fulden Buyukozturk (2010)
10.1016/S0168-3659(02)00323-1
A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration.
B. Lundberg (2003)
10.1007/s11095-009-9924-0
The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs
S. Shugarts (2009)
10.1016/S0378-5173(02)00018-2
Susceptibility of the H2-receptor antagonists cimetidine, famotidine and nizatidine, to metabolism by the gastrointestinal microflora.
A. Basit (2002)
10.1016/S0378-5173(00)00344-6
Biopharmaceutics and pharmacokinetics in drug research.
R. Panchagnula (2000)
10.1002/JPS.20434
Transport of levovirin prodrugs in the human intestinal Caco-2 cell line.
Fujun Li (2006)
10.1128/AAC.39.8.1671
Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole.
T. Chin (1995)
10.1016/S0168-3659(97)01633-7
USP Dissolution Apparatus III (reciprocating cylinder) for screening of guar-based colonic delivery formulations
D. Wong (1997)
10.1002/jps.21271
An investigation into the digestion of chitosan (noncrosslinked and crosslinked) by human colonic bacteria.
E. McConnell (2008)
10.1021/mp800128y
Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation.
I. Kovacevic (2009)
10.1016/J.ADDR.2007.08.017
The effects of pharmaceutical excipients on drug disposition.
Talia R Buggins (2007)
10.1128/JB.00239-07
Low Concentrations of Bile Salts Induce Stress Responses and Reduce Motility in Bacillus cereus ATCC 14570
Simen M Kristoffersen (2007)
10.1208/ps040440
An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine
B. Johnson (2008)
10.1007/s11095-007-9523-x
The Use of BDDCS in Classifying the Permeability of Marketed Drugs
L. Benet (2007)
10.1124/DMD.32.11.1311
Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes.
J. Lam (2004)
10.1016/j.ijpharm.2011.03.033
Applicability of sucrose laurate as surfactant in solid dispersions prepared by melt technology.
A. Szűts (2011)
10.1111/j.1365-2125.1995.tb04466.x
The effects of pharmaceutical excipients on small intestinal transit.
D. Adkin (1995)
10.1016/J.JCONREL.2007.08.021
Effect of excipients on breast cancer resistance protein substrate uptake activity.
T. Yamagata (2007)
10.1023/A:1015849700421
Variation in Gastrointestinal Transit of Pharmaceutical Dosage Forms in Healthy Subjects
Alastair J. Coupe (1991)
Aulton's pharmaceutics: the design and manufacture of medicines
Me Aulton (2007)
10.3109/02713683.2011.631722
A Comparison of Active Ingredients and Preservatives Between Brand Name and Generic Topical Glaucoma Medications Using Liquid Chromatography-Tandem Mass Spectrometry
M. Kahook (2012)
10.1016/S1095-6433(00)00330-5
The control of gut motility.
C. Olsson (2001)
10.1023/A:1016473601633
Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions
L. Yu (2004)
10.1016/j.ejps.2010.05.002
Intestinal permeability enhancement of levothyroxine sodium by straight chain fatty acids studied in MDCK epithelial cell line.
Dimple Pabla (2010)
10.1016/J.IJPHARM.2007.06.018
A critical evaluation of fasted state simulating gastric fluid (FaSSGF) that contains sodium lauryl sulfate and proposal of a modified recipe.
A. Aburub (2008)
10.1208/s12248-008-9040-9
Summary Workshop Report: Bioequivalence, Biopharmaceutics Classification System, and Beyond
J. Polli (2008)
[Endodontic surgery in immature tooth roots].
Firedrich Kreter (1975)
10.1002/jps.21903
Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis.
S. Murdande (2010)
10.1007/BF03189322
Gastric juice as a dissolution medium: Surface tension and pH
M. Efentakis (2010)
10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J
Intestinal permeation enhancers.
B. Aungst (2000)
10.1016/J.CES.2012.01.046
Process-induced phase transformations in a pharmaceutically relevant salt-free form system
Haiyan Qu (2012)
10.1208/s12248-008-9027-6
In Vitro Studies are Sometimes Better than Conventional Human Pharmacokinetic In Vivo Studies in Assessing Bioequivalence of Immediate-Release Solid Oral Dosage Forms
J. Polli (2008)
10.1016/S0378-5173(01)00867-5
Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability.
S. G. Kapsi (2001)
10.1023/A:1007576713216
A Comparison of the Solubility of Danazol in Human and Simulated Gastrointestinal Fluids
B. L. Pedersen (2004)
10.3109/03639045.2012.687745
Single non-ionic surfactant based self-nanoemulsifying drug delivery systems: formulation, characterization, cytotoxicity and permeability enhancement study
Mithun Bandivadekar (2013)
10.1016/0169-409X(96)00009-9
Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption.
L. X. Yu (1996)
10.1124/dmd.106.014217
Improvement of the Oral Drug Absorption of Topotecan through the Inhibition of Intestinal Xenobiotic Efflux Transporter, Breast Cancer Resistance Protein, by Excipients
T. Yamagata (2007)
10.1023/A:1018918907670
Effect of Sodium Acid Pyrophosphate on Ranitidine Bioavailability and Gastrointestinal Transit Time
K. Koch (1993)
10.1201/9780367801021
Photostability of Drugs and Drug Formulations
H. Tønnesen (2004)
10.1208/s12248-008-9036-5
Application of the Biopharmaceutical Classification System in Clinical Drug Development—An Industrial View
J. Cook (2008)
10.1016/J.EJPB.2006.07.009
Application of sucrose fatty acid esters in transdermal therapeutic systems.
G. Csóka (2007)
10.2165/00003088-199936030-00004
Drug, Meal and Formulation Interactions Influencing Drug Absorption After Oral Administration
D. Fleisher (1999)
10.1177/00970002042006005
A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals.
M. Martinez (2002)
10.1023/A:1011984216775
Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms
J. Dressman (2004)
PHASE-SOLUBILITY TECHNIQUES
T. Higuchi (1965)
10.1016/S0378-5173(01)00794-3
Colonic metabolism of ranitidine: implications for its delivery and absorption.
A. Basit (2001)
10.1002/jps.2600840425
Metabolism of omeprazole by gut flora in rats.
K. Watanabe (1995)
10.1016/0378-5173(95)04137-0
Effect of penetration enhancers on flurbiprofen permeation through rat skin
S. Chi (1995)
10.1016/J.EJPS.2004.12.010
Amphiphilic amino acid copolymers as stabilizers for the preparation of nanocrystal dispersion.
J. Lee (2005)
10.1007/b114443
Stability of Drugs and Dosage Forms
S. Yoshioka (2002)
10.1016/J.FARMAC.2005.08.007
In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies.
P. Sharma (2005)
10.1002/JPS.1127
Effect of common excipients on Caco-2 transport of low-permeability drugs.
B. Rege (2001)
10.1016/S0032-9592(99)00052-7
The combined effects of pH and temperature on penicillin G decomposition and its stability modeling
A. Kheirolomoom (1999)
10.1007/978-0-387-74901-3
Drug Absorption Studies
C. Ehrhardt (2008)
10.1016/S0169-409X(96)00423-1
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.
C. Lipinski (1997)
10.1023/A:1011992518592
Human Drug Absorption Kinetics and Comparison to Caco-2 Monolayer Permeabilities
J. Polli (2004)
10.1023/A:1016212804288
A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
G. Amidon (2004)
10.1016/J.EJPB.2005.03.002
Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds.
M. Vertzoni (2005)
10.1016/j.addr.2011.06.015
Molecular origins of surfactant-mediated stabilization of protein drugs.
H. Lee (2011)
10.1016/0016-5085(92)91789-7
Transit through the proximal colon influences stool weight in the irritable bowel syndrome.
M. Vassallo (1992)
10.1056/NEJM198110013051403
Inactivation of digoxin by the gut flora: reversal by antibiotic therapy.
J. Lindenbaum (1981)
10.4103/0250-474X.91585
Mixed Hydrotropy: Novel Science of Solubility Enhancement
R. K. Maheshwari (2011)
10.1016/S1388-2457(98)00081-9
Modulation of intracortical excitability for different muscles in the upper extremity: paired magnetic stimulation study with focal versus non-focal coils
T. Shimizu (1999)
10.1063/1.3453713
Molecular basis for polyol-induced protein stability revealed by molecular dynamics simulations.
Fu-feng Liu (2010)
10.1152/ajpgi.00102.2009
Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
A. Dahan (2009)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar